Yan H, Liu J, Zhang Z, Chen S, et al. Canagliflozin attenuates CMR-quantified myocardial fibrosis in individuals with type 2 diabetes mellitus at high cardiovascular risk: a randomised open-label controlled trial. Diabetologia 2026 Feb 24. doi: 10.1007/s00125-026-06682.
PMID: 41735586